Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
383 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04502095 | Prophylactic Antibiotics for Urinary Tract Infections After Robot-Assisted Radical Cystectomy | completed | Phase 4 | 89 | Roswell Park Cancer InstituteOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT04876248 | Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant | active not recruiting | Phase 2 | 4 | Roswell Park Cancer InstituteOTHER | 1 | Sep 25, 2026 |
| clinicaltrials |
| NCT06871410 | Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | recruiting | Phase 1 | 26 | Roswell Park Cancer InstituteOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07182240 | Pilot Study of Line-Field Confocal Optical Coherence Tomography for Detection of Mohs Micrographic Surgery Margins of Basal Cell Carcinomas | recruiting | N/A | 60 | Roswell Park Cancer InstituteOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT04032418 | Pembrolizumab Every 12 Weeks Versus Every 3 Weeks in Treating Patients With Non-small Cell Lung Cancer | active not recruiting | Phase 2 | 9 | Roswell Park Cancer InstituteOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06733363 | A Cruciferous Vegetable Eating Program for the Reduction of Cancer Recurrence and Progression in Patients With Non-muscle Invasive Bladder Cancer | recruiting | Phase 2 | 344 | Roswell Park Cancer InstituteOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07489287 | GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer | recruiting | Phase 1 | 18 | Roswell Park Cancer InstituteOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT06943664 | Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung Cancer | withdrawn | Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06968195 | Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or Metastatic GPC3 Expressing Hepatocellular Carcinoma | suspended | Phase 1 | 24 | Roswell Park Cancer InstituteOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07039630 | A Food Security Intervention for the Prevention of Cancer in Low-income Families | suspended | N/A | 50 | Roswell Park Cancer InstituteOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07075705 | Transperineal Micro-ultrasound for the Detection of Prostate Cancer During Biopsy | recruiting | N/A | 138 | Roswell Park Cancer InstituteOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT04269213 | CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old | completed | Phase 2 | 21 | Roswell Park Cancer InstituteOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT06681077 | A Community Health Education Intervention for Increasing Community-driven Actions to Reduce the Cancer Burden in Western New York | recruiting | N/A | 500 | Roswell Park Cancer InstituteOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07543172 | CIMAvax-EGF With KRAS G12C Inhibitor for the Treatment of Advanced, KRAS G12C Mutated Non Small Cell Lung Cancer | not yet recruiting | Phase 2 | 29 | Roswell Park Cancer InstituteOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05756166 | Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer | terminated | Phase 1 / Phase 2 | 5 | Roswell Park Cancer InstituteOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT01959698 | Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma | active not recruiting | Phase 1 | 29 | Roswell Park Cancer InstituteOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07167225 | Carcinogen and Toxicant Exposure Among Young Adults Who Co-Use Cigarettes, E-cigarettes and Cannabis (Co-Tox Study) | recruiting | — | 150 | Roswell Park Cancer InstituteOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07718672 | Hotspot Stereotactic Ablative Radiotherapy Versus Traditional Stereotactic Ablative Radiotherapy for the Treatment of Early-Stage Non-Small Cell Lung Cancer | recruiting | Phase 2 | 200 | Roswell Park Cancer InstituteOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT06414317 | An Education and Navigation Support Tool to Improve Participation in Care Coordination Among Patients With Locally Advanced, Metastatic and Unresectable Bladder Cancer and Their Caregivers | active not recruiting | N/A | 12 | Roswell Park Cancer InstituteOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT04073745 | Single Fraction Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Non-small Cell Lung Cancer | active not recruiting | Phase 1 | 50 | Roswell Park Cancer InstituteOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT03965234 | Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases | recruiting | Phase 1 / Phase 2 | 99 | Roswell Park Cancer InstituteOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT05893940 | Low-Intensity Mechanical Stimulation for Hematologic Malignancy Patients | recruiting | N/A | 75 | Roswell Park Cancer InstituteOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT06011772 | EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer | active not recruiting | Early Phase 1 | 2 | Roswell Park Cancer InstituteOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07553819 | Home-Based Respiratory Muscle Training and Aerobic Exercise Programs to Improve Lung Health in Current and Former Cigarette Smokers | not yet recruiting | N/A | 200 | Roswell Park Cancer InstituteOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT06202066 | Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas | suspended | Phase 2 | 60 | Roswell Park Cancer InstituteOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07714018 | Comparing Two Weight Loss Programs for the Prevention of Kidney Cancer Progression Among Patients With Small Renal Masses on Active Surveillance | recruiting | N/A | 20 | Roswell Park Cancer InstituteOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT05787834 | Home-based Respiratory Muscle Training for Minimizing Side Effects in Patients Undergoing Treatment for Cancer | recruiting | N/A | 130 | Roswell Park Cancer InstituteOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07017829 | GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer | recruiting | Phase 2 | 28 | Roswell Park Cancer InstituteOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07214298 | Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma | recruiting | Phase 1 / Phase 2 | 35 | Roswell Park Cancer InstituteOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT06627751 | Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease | recruiting | Phase 2 | 28 | Roswell Park Cancer InstituteOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT06995508 | Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial | recruiting | Phase 2 | 66 | Roswell Park Cancer InstituteOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07439471 | Understanding Tobacco and Cannabis Co-Use Practices: Initiation, Escalation, and Maintenance | recruiting | — | 40 | Roswell Park Cancer InstituteOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT05231122 | Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer | recruiting | Phase 2 | 80 | Roswell Park Cancer InstituteOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT06622005 | SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 | 15 | Roswell Park Cancer InstituteOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT06055231 | PK/PD of Vaping THC-containing Liquids vs. Smoked Cannabis | not yet recruiting | Phase 1 | 40 | Roswell Park Cancer InstituteOTHER | 0 | Aug 12, 2026 | clinicaltrials |
| NCT06323044 | MedSupport Intervention to Identify and Address Barriers to Pediatric Medication Adherence | recruiting | N/A | 150 | Roswell Park Cancer InstituteOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT06827054 | Psilocybin With Psychotherapy for Improving Chronic Pain in Cancer Patients Requiring Opioids | not yet recruiting | Phase 2 | 20 | Roswell Park Cancer InstituteOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT02955290 | CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer | active not recruiting | Phase 1 / Phase 2 | 51 | Roswell Park Cancer InstituteOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT02455557 | SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma | active not recruiting | Phase 2 | 66 | Roswell Park Cancer InstituteOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT06305598 | Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer | active not recruiting | Phase 1 | 3 | Roswell Park Cancer InstituteOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT07745023 | Mind-Body Interventions for the Improvement of Quality of Life, Stress, and Sleep Quality Among Survivors of Breast, Prostate, Endometrial, or Colorectal Cancer | not yet recruiting | N/A | 30 | Roswell Park Cancer InstituteOTHER | 0 | Aug 4, 2026 | clinicaltrials |
| NCT04646434 | Brain and Pelvic Floor Muscle Activity of Patients Who Had or Are Undergoing Robot-Assisted Radical Prostatectomy | suspended | N/A | 100 | Roswell Park Cancer InstituteOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07679334 | Phase I Trial of Pacritinib in Combination With Venetoclax and Azacitidine for the Treatment of Accelerated and Blast Phase Myeloproliferative Neoplasms | not yet recruiting | Phase 1 | 20 | Roswell Park Cancer InstituteOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT06206863 | Community-Based Physical Activity Intervention for Underserved Cancer Survivors | recruiting | N/A | 200 | Roswell Park Cancer InstituteOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT06565260 | Community-Based Exercise and Nutrition Training and Education Program for Cancer Survivors | recruiting | N/A | 150 | Roswell Park Cancer InstituteOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT06029517 | A Sugar-Sweetened Beverage Reduction Intervention for Native American Men | completed | N/A | 48 | Roswell Park Cancer InstituteOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT04348747 | Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer | recruiting | Phase 2 | 23 | Roswell Park Cancer InstituteOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT06863402 | Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype | recruiting | Phase 2 | 32 | Roswell Park Cancer InstituteOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT06798701 | Virtual Reality for Symptom Management in Patients Undergoing Hematopoietic Stem Cell Transplantation | active not recruiting | N/A | 21 | Roswell Park Cancer InstituteOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT03384836 | Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery | suspended | Phase 1 / Phase 2 | 47 | Roswell Park Cancer InstituteOTHER | 1 | Jul 15, 2026 | clinicaltrials |
Data updated 24 hours agoSource updated unknownsource: clinicaltrials